Lenalidomide Glenmark (Lenalidomide)

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone‑marrow clones.

• Multiple Myeloma: improves progression‑free survival and overall response rates, especially in relapsed or refractory disease.
• Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and improves peripheral blood counts.
• Maintenance Therapy after Autologous Stem Cell Transplant in Multiple Myeloma: prolongs remission duration and delays disease progression.

• Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity. This leads to ubiquitination and degradation of transcription factors Ikaros and Aiolos, resulting in anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that suppress malignant plasma cells and abnormal myeloid clones.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count increasing infection risk.
• Thrombocytopenia: lowered platelet levels leading to bleeding tendencies.
• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may cause dehydration.
• Constipation: difficulty passing stool.
• Rash: mild skin eruptions.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Secondary primary malignancies: emergence of new cancers.
• Hepatic failure: significant liver enzyme elevation or dysfunction.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Lenalidomide requires careful monitoring and specific safety measures before and during therapy.

• Pregnancy Contraindication: teratogenic; avoid use in pregnant women and ensure effective contraception.
• Thrombosis Risk: assess for clotting risk and consider prophylactic anticoagulation when indicated.
• Hematologic Monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia.
• Renal Impairment: adjust dose in patients with reduced kidney function.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid)

• Combined use with thalidomide: markedly increases risk of peripheral neuropathy and thromboembolic events.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce lenalidomide exposure and efficacy.
• Anticoagulants (warfarin): heightened bleeding risk; monitor coagulation parameters closely.

Moderate Interactions (Monitor Closely)

• NSAIDs (ibuprofen, naproxen): may exacerbate renal toxicity.
• Antibiotics that inhibit renal transport (e.g., trimethoprim): could increase lenalidomide plasma levels.
• Live vaccines: contraindicated due to immunosuppressive effects; avoid administration during treatment.